Brief: Pharming Publishes Data From Phase 3 Study Of Leniolisib

Pharming

07/12/2022 06:05

Dec 7 (Reuters) - Pharming Group NV  PHAR.AS :
    * ANNOUNCES PUBLICATION OF DATA FROM PHASE 3 STUDY OF
LENIOLISIB
IN PATIENTS WITH APDS IN ASH'S BLOOD
    * LENIOLISIB WAS WELL TOLERATED AND SIGNIFICANT IMPROVEMENT
OVER
PLACEBO WAS NOTABLE IN CO-PRIMARY ENDPOINTS, REFLECTING A
FAVORABLE IMPACT ON PATIENTS' IMMUNE DYSREGULATION AND
DEFICIENCY

Source text for Eikon:  ID:nCNWNYzFha 
Further company coverage:  PHAR.AS 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))